Ferrous sulfate with folic acid, ascorbic acid and b group vitamins oral
- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Soft capsules containing ferrous sulfate, folic acid, thiamine hydrochloride (Vitamin B1), riboflavine (Vitamin B2), nicotinamide (Vitamin B3) and ascorbic Acid (Vitamin C).
Treatment of iron deficiency anaemia
Vitamin deficiency - multiple
One capsule to be taken three times a day with meals.
Hereditary fructose intolerance
Precautions and Warnings
Contains soya or soya derivative
Presentations with sorbitol unsuitable in hereditary fructose intolerance
Iron salts may exacerbate diarrhoea in patients with inflammatory bowel disease.
Pregnancy and Lactation
Use ferrous sulfate, folic acid, ascorbic acid and B vitamin capsules with caution during pregnancy.
During pregnancy, the maternal need for iron increases to fulfil the requirements of the foetus and placenta. Although the volume of maternal plasma increases, the number of erthyrocytes does not, thus leading to a decrease in haemoglobin value. Consequently, a pregnant woman needs about 5 mg of iron per day, which cannot be adequately covered by diet alone. Iron supplements are recommended if haemoglobin levels fall below 100 g/litre (Schaefer, 2015).
The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Ferrous sulfate, folic acid, ascorbic acid and B vitamin capsules are considered safe for use in pregnancy
The use of relatively high doses of iron in breastfeeding mothers is probably not contraindicated, due to the fact that iron transports very poorly into the milk compartment. However, no information is available for this product containing a range of additional vitamins.
Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
Specialist advice is available from the UK Drugs in Lactation Advisory Service at https://www.midlandsmedicines.nhs.uk/content.asp?section=6&subsection=17&pageIdx=1
Advise patients that iron is best absorbed when taken on an empty stomach but may be taken after food to reduce gastrointestinal symptoms.
Inform patients that treatment might cause darkening of the stool.
Discolouration of stools
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Last Full Review Date: May 2017
Drugs During Pregnancy and Lactation: Treatment Options and Risk Assessment, 3rd edition (2015) ed. Schaefer, C., Peters, P. and Miller, R. Elsevier, London.
Joint Formulary Committee. British National Formulary. 73rd ed. London: BMJ Group and Pharmaceutical Press; 2017.
Summary of Product Characteristics: Ironorm Capsules. Wallace Manufacturing Chemists Ltd. Revised May 2016.
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.